These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1146 related articles for article (PubMed ID: 21818509)

  • 1. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcipotriene plus betamethasone dipropionate topical suspension for the treatment of mild to moderate psoriasis vulgaris on the body: a randomized, double-blind, vehicle-controlled trial.
    Menter A; Gold LS; Bukhalo M; Grekin S; Kempers S; Boyce BM; Ganslandt C; Villumsen J; Lebwohl M
    J Drugs Dermatol; 2013 Jan; 12(1):92-8. PubMed ID: 23377334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of calcipotriene plus betamethasone dipropionate topical suspension on the hypothalamic-pituitary-adrenal axis and calcium homeostasis in subjects with extensive psoriasis vulgaris: an open, non-controlled, 8-week trial.
    Silver S; Tuppal R; Gupta AK; Clonier F; Olesen M; Leeder R; Taraska V
    J Drugs Dermatol; 2013 Aug; 12(8):882-7. PubMed ID: 23986161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and long-term safety assessment of a two-compound ointment containing calcipotriene/betamethasone dipropionate (Taclonex/Daivobet/Dovobet ointment): hypothalamic-pituitary-adrenal axis function in patients with psoriasis vulgaris.
    Fleming C; Ganslandt C; Leese GP
    J Drugs Dermatol; 2010 Aug; 9(8):969-74. PubMed ID: 20684147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
    Jemec GB; Ganslandt C; Ortonne JP; Poulin Y; Burden AD; de Unamuno P; Berne B; Figueiredo A; Austad J
    J Am Acad Dermatol; 2008 Sep; 59(3):455-63. PubMed ID: 18694678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks.
    Singh S; Reddy DC; Pandey SS
    J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):61-5. PubMed ID: 10863225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.
    McCormack PL
    Am J Clin Dermatol; 2011 Dec; 12(6):421-4. PubMed ID: 21967117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients.
    Campione E; Mazzotta A; Paternò EJ; Diluvio L; Prinz JC; Chimenti S
    Acta Derm Venereol; 2009; 89(3):288-91. PubMed ID: 19479128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcipotriene 0.005% and betamethasone dipropionate 0.064% combination topical suspension (Taclonex Scalp).
    Scheinfeld NS
    Skinmed; 2011; 9(3):179-80. PubMed ID: 21675498
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
    Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
    Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
    Kragballe K; Noerrelund KL; Lui H; Ortonne JP; Wozel G; Uurasmaa T; Fleming C; Estebaranz JL; Hanssen LI; Persson LM
    Br J Dermatol; 2004 Jun; 150(6):1167-73. PubMed ID: 15214905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
    Bagel J; Zapata J; Nelson E
    J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment.
    Anstey AV; Kragballe K
    Int J Dermatol; 2006 Aug; 45(8):970-5. PubMed ID: 16911387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis.
    Kin KC; Hill D; Feldman SR
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):789-97. PubMed ID: 27089906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.